Role of NRG1 coalescence for treatment of lung cancer in patients

Author(s): Hooria Ghias, Sayed Shahbal, Ali Ibrahim Noshili, Amal Mohammad Hamdi, Mohammed Dakhiallah M Altobaiti, Mazen Ayidh S Aladhyani, Sultan Mohammed Somily, Mohammed Assad Alnawwar, Mohammad Mustaffa Zilaei, Zahra Hadi Alhulaysi, Amrah Hadi Alhileesi, Manar Salah Aldhmashi, Ihtiram Ali Alruwaili, Turki Ali Haloosh, Shuruq Mubarak Al-Ruwaili, and Bashair Yasser Ghaleb Dabbour

Gene-targeted treatments for lung cancer have significantly increased survival rates when compared to conventional chemotherapy. In both Europe and the United States, researchers are looking into the therapeutic potential of a gene fusion called Neuregulin 1 (NRG1). The purpose of this review is to highlight the importance of this novel fusion in the treatment of lung cancer and the most recent achievements in this field. In a broad spectrum of cancers, oncogenic gene fusions originate from structural DNA rearrangements that promote uncontrolled cell proliferation. The genes of crossbreeds, as a result, drugs to inhibit cell growth and proliferation have been created. Lung cancer therapy is increasingly focusing on oncogene fusions such as ALK, RET, NTRK, and ROS1, among others. Many diseases have been linked to NRG gene fusions, which have been linked to a variety of solid tumors (including kidney and pancreatic cancer, breast and colorectal cancer, and lung cancer). As has been the case for decades, oncology treatment will continue to evolve, moving from a focus on the disease’s genesis to a more genetically-based approach. In addition to improving survival rates, the increased availability of these drugs has sparked a renewed interest in finding new therapies.